Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Recruiting · NCT07473128 · Interventional (participants receive a specific treatment) · Lead sponsor: Pharmacosmos A/S
View the official record on ClinicalTrials.gov →Interventions studied
Saline (0.9% NaCl)Trilaciclib
What this trial is about
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
- Complete recovery from prior anti-tumor surgical procedures
- Measurable and evaluable disease through tumor assessment
- Willingness to participate and sign informed consent form
Exclusion criteria
- Extensive Stage Small Cell Lung Cancer
- Active cardiovascular disease
- Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
- Pregnant or nursing women
Where it is running
1 location listed across 1 US state.
- Pharmacosmos Investigational Site - Oakland, California, United States